These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27487991)

  • 1. Therapeutic Value of Adeno Associated Virus as a Gene Therapy Vector for Parkinson's Disease - A Focused Review.
    Singh A; Sen D
    Curr Gene Ther; 2016; 16(4):278-286. PubMed ID: 27487991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in the application of gene therapy for Parkinson's disease with adeno-associated virus].
    Chen Y; Lü YH; Li ZF
    Yao Xue Xue Bao; 2014 May; 49(5):576-81. PubMed ID: 25151724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.
    Kaplitt MG; Feigin A; Tang C; Fitzsimons HL; Mattis P; Lawlor PA; Bland RJ; Young D; Strybing K; Eidelberg D; During MJ
    Lancet; 2007 Jun; 369(9579):2097-105. PubMed ID: 17586305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.
    Ozawa K; Fan DS; Shen Y; Muramatsu S; Fujimoto K; Ikeguchi K; Ogawa M; Urabe M; Kume A; Nakano I
    J Neural Transm Suppl; 2000; (58):181-91. PubMed ID: 11128607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current development of adeno-associated viral vectors.
    Romano G
    Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scientific rationale for the development of gene therapy strategies for Parkinson's disease.
    Björklund T; Kirik D
    Biochim Biophys Acta; 2009 Jul; 1792(7):703-13. PubMed ID: 19254760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
    Kelly MJ; O'Keeffe GW; Sullivan AM
    Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease.
    Diaz-Nido J
    Curr Opin Investig Drugs; 2010 Jul; 11(7):813-22. PubMed ID: 20571977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
    Brown N; Song L; Kollu NR; Hirsch ML
    Hum Gene Ther; 2017 Jun; 28(6):450-463. PubMed ID: 28490211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Present status and future prospects for gene therapy in Parkinson's disease].
    Muramatsu S
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1461-6. PubMed ID: 13677895
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer gene therapy using adeno-associated virus vectors.
    Park K; Kim WJ; Cho YH; Lee YI; Lee H; Jeong S; Cho ES; Chang SI; Moon SK; Kang BS; Kim YJ; Cho SH
    Front Biosci; 2008 Jan; 13():2653-9. PubMed ID: 17981740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
    Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
    Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson's disease treatment.
    Lee MH; Kang S; Um KH; Lee SW; Hwang H; Baek K; Choi JW
    J Transl Med; 2024 Jan; 22(1):53. PubMed ID: 38218903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-Generation Gene Therapy for Parkinson's Disease Using Engineered Viral Vectors.
    Björklund T; Davidsson M
    J Parkinsons Dis; 2021; 11(s2):S209-S217. PubMed ID: 34366370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral Vector-Based Modeling of Neurodegenerative Disorders: Parkinson's Disease.
    Fischer DL; Gombash SE; Kemp CJ; Manfredsson FP; Polinski NK; Duffy MF; Sortwell CE
    Methods Mol Biol; 2016; 1382():367-82. PubMed ID: 26611600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant adeno-associated virus as delivery vector for gene therapy--a review.
    Lu Y
    Stem Cells Dev; 2004 Feb; 13(1):133-45. PubMed ID: 15068701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies of gene therapy for Parkinson's disease].
    Mochizuki H
    Rinsho Shinkeigaku; 2009 Nov; 49(11):753-5. PubMed ID: 20030202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for Parkinson's disease.
    Mochizuki H; Mizuno Y
    J Neural Transm Suppl; 2003; (65):205-13. PubMed ID: 12946058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.